Evaluating the Impact of Lenalidomide on Bone Marrow Cancer Treatment: Monitoring White Blood Cell, Hemoglobin, and Platelet Levels
BACKGROUND: Lenalidomide (LEN), also known as Revlimid, is a drug used to treat multiple myeloma (MM), smoldering myeloma, and myelodysplastic syndromes. It is used as a first-line treatment for MM, along with dexamethasone. OBJECTIVE: To investigate the effects of LEN on the function of bone marrow...
Saved in:
Main Authors: | Hiba Jumaa Hussein, Lara Ali Nazar, Hamsa Ghwamer Ghazi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
Series: | Journal of Applied Hematology |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/joah.joah_104_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01) -
A multiscale model of the bone marrow and hematopoiesis
by: Ariosto Silva, et al.
Published: (2011-03-01) -
LENALIDOMIDE RETREATMENT IN A PATIENT WITH RELAPSED MULTIPLE MYELOMA WHO HAD PREVIOUSLY RESPONDED TO LENALIDOMIDE
by: Vincenzo Federico
Published: (2014-08-01) -
Detection of focal lesions in the clot section with negative bone marrow aspirate and trephine biopsy—A series of 5 cases
by: Vandana Bhatti, et al.
Published: (2023-07-01) -
Diagnosis of AL amyloidosis on bone marrow aspirate smears - A Case Report
by: Supraja Sundaram, et al.
Published: (2022-01-01)